Susan Adele Greenfield,Henry Tu,Paul Morrill,Sara Rates-Garcia,Chris Pepper,Chris Fegan
申请号：
GB201601585
公开号：
GB2546773A
申请日:
2016.01.28
申请国别(地区):
GB
年份:
2017
代理人:
摘要：
An inhibitor of the synthesis and/or activity of the T14 peptide (SEQ ID NO: 3, AEFHRWSSYMVHWK) derived from the C-terminus of tailed acetylcholinesterase (T-AchE) is disclosed for use in treating, ameliorating or preventing cancer or metastatic disease. Methods of screening a candidate agent to test whether or not the compound has efficacy for treating, preventing or ameliorating cancer or metastatic disease are also disclosed as are methods of screening a compound to test whether or not the compound causes cancer. SEQ ID NO: 3 is disclosed in diagnostic methods as a biomarker or prognostic indicator for cancer or metastatic disease. Preferably, the inhibitor inhibits the interaction or translocation of the T14 peptide with/to an allosteric site on alpha-7 nicotinic receptors (cholinergic receptor nicotinic alpha 7, NACHRA7, CHRNA7-2). Preferably, the cancer is leukaemia, lymphocytic leukaemia, chronic lymphocytic leukaemia (CLL), myeloid leukaemia, acute myeloid leukaemia (AML), multiple myeloma, breast cancer or plasmacytoma.
